Captor Therapeutics Publishes Q1 2023 Financial Results May 30, 2023 08:00AM
Captor Therapeutics Announces Three-Year Strategic Objectives Mar 7, 2023 02:00AM
Captor Therapeutics Reports Q3 2022 Results and Provides Business Update Nov 25, 2022 08:00AM
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma Aug 10, 2022 01:00AM
Captor Therapeutics to Host R&D Day on May 18, 2022 May 5, 2022 03:00AM


Apr 12, 2022 01:00AM Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
Apr 11, 2022 02:00AM Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022
Jan 13, 2022 09:56AM Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma
Oct 28, 2019 07:30AM Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
Oct 28, 2019 07:30AM Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals